September 30, 2025 • 4 mins
Welcome to Ozempic Weightloss Unlocked, where we dive into the latest breakthroughs and controversies surrounding Ozempic, its medical use, and its impact on everyday wellness.
The big headline this month is the arrival of a new pill form of semaglutide, the main ingredient in Ozempic. According to The New England Journal of Medicine, people who took this daily pill lost almost 14 percent of their body weight over 64 weeks, compared to just 2 percent for those on a placebo. Fifty percent of the patients shed at least 15 percent of their weight, with nearly a third losing 20 percent or more. Novo Nordisk, the company that makes Ozempic, announced even stronger results for those who stuck to their treatment plan, with close to 17 percent average weight loss. This pill, pending approval, could be a game changer for people who prefer not to take injections.
On the injectable front, clinical trials featured in The Lancet indicate that a higher 7.2 milligram weekly dose of semaglutide in adults without diabetes led to almost 19 percent average weight loss, higher than what’s seen with lower doses. These numbers highlight ongoing efforts to increase the effectiveness of Ozempic for those struggling with obesity.
Yet, it’s crucial to balance these promising results with real-world insights. The Mayo Clinic and NYU Langone Health recently compared Ozempic’s results to traditional weight loss surgery, like gastric bypass and sleeve gastrectomy. Their research revealed that surgery is five times more effective than GLP-1 drugs such as Ozempic, with surgical patients losing an average of 58 pounds after two years versus just 12 pounds for those on the drug for six months. Experts also noted that only 30 percent of patients stick with GLP-1 drugs for longer than a year, and real-world weight loss may be lower than trial results suggest. Surgery, however, isn’t without its risks, including potential infections, blood clots, and hernias, and requires strict diet and lifestyle changes afterward.
Turning to genetics, Cleveland Clinic research shows that the effectiveness of Ozempic may depend on your DNA. A specific variant in the Neurobeachin gene seems to make some people much more responsive to these medications, leading to 82 percent higher odds of substantial weight loss. This new insight could help doctors tailor treatments so patients get therapies most suited to their genetic profile.
Lifestyle stakes are high, and so are concerns about side effects and safety. Recent studies report that Ozempic may cause severe conditions such as gastroparesis, bowel blockages, pancreatic and kidney injuries, and vision problems. Even hair loss is emerging as a potentially significant side effect, especially for women—according to recent findings, female users experienced about twice the rate of hair loss compared to those not using Ozempic.
Because of these risks, there are currently over two thousand active lawsuits against Novo Nordisk and other GLP-1 manufacturers, with ongoing multidistrict litigation. These lawsuits allege that the companies did not give enough warning about the dangers, and some patients claim life-changing or life-threatening complications.
Compounded GLP-1 drugs, made in pharmacies rather than by pharmaceutical companies, became popular when Ozempic was in short supply. However, the FDA warns that compounded drugs can be risky because they’re not evaluated for safety or effectiveness. While the shortage has officially ended, compounded formulations remain in circulation.
If you are considering Ozempic—whether as a pill, injection, or a compounded version—talk with your healthcare provider and review your health history, genetic background, and lifestyle goals. Widespread interest has led to changing availability, promising new forms, and more transparent labeling, especially after recent updates about kidney and pancreatic risks.
To sum up, Ozempic continues to make waves as both a treatment for diabetes and a potent tool for weight loss. With fresh news about new pill forms, higher effective doses, genetic influences, and ongoing legal cases, it’s important to stay informed and make choices based on both science and your personal health needs.
Thanks for tuning in to Ozempic Weightloss Unlocked. Don’t forget to subscribe to stay up to date on the latest developments. This has been a Quiet Please production, for more check out quiet please dot ai.
Some great Deals https://amzn.to/49SJ3Qs
For more check out http://www.quietplease.ai
This content was created in partnership and with the help of Artificial Intelligence AI
The big headline this month is the arrival of a new pill form of semaglutide, the main ingredient in Ozempic. According to The New England Journal of Medicine, people who took this daily pill lost almost 14 percent of their body weight over 64 weeks, compared to just 2 percent for those on a placebo. Fifty percent of the patients shed at least 15 percent of their weight, with nearly a third losing 20 percent or more. Novo Nordisk, the company that makes Ozempic, announced even stronger results for those who stuck to their treatment plan, with close to 17 percent average weight loss. This pill, pending approval, could be a game changer for people who prefer not to take injections.
On the injectable front, clinical trials featured in The Lancet indicate that a higher 7.2 milligram weekly dose of semaglutide in adults without diabetes led to almost 19 percent average weight loss, higher than what’s seen with lower doses. These numbers highlight ongoing efforts to increase the effectiveness of Ozempic for those struggling with obesity.
Yet, it’s crucial to balance these promising results with real-world insights. The Mayo Clinic and NYU Langone Health recently compared Ozempic’s results to traditional weight loss surgery, like gastric bypass and sleeve gastrectomy. Their research revealed that surgery is five times more effective than GLP-1 drugs such as Ozempic, with surgical patients losing an average of 58 pounds after two years versus just 12 pounds for those on the drug for six months. Experts also noted that only 30 percent of patients stick with GLP-1 drugs for longer than a year, and real-world weight loss may be lower than trial results suggest. Surgery, however, isn’t without its risks, including potential infections, blood clots, and hernias, and requires strict diet and lifestyle changes afterward.
Turning to genetics, Cleveland Clinic research shows that the effectiveness of Ozempic may depend on your DNA. A specific variant in the Neurobeachin gene seems to make some people much more responsive to these medications, leading to 82 percent higher odds of substantial weight loss. This new insight could help doctors tailor treatments so patients get therapies most suited to their genetic profile.
Lifestyle stakes are high, and so are concerns about side effects and safety. Recent studies report that Ozempic may cause severe conditions such as gastroparesis, bowel blockages, pancreatic and kidney injuries, and vision problems. Even hair loss is emerging as a potentially significant side effect, especially for women—according to recent findings, female users experienced about twice the rate of hair loss compared to those not using Ozempic.
Because of these risks, there are currently over two thousand active lawsuits against Novo Nordisk and other GLP-1 manufacturers, with ongoing multidistrict litigation. These lawsuits allege that the companies did not give enough warning about the dangers, and some patients claim life-changing or life-threatening complications.
Compounded GLP-1 drugs, made in pharmacies rather than by pharmaceutical companies, became popular when Ozempic was in short supply. However, the FDA warns that compounded drugs can be risky because they’re not evaluated for safety or effectiveness. While the shortage has officially ended, compounded formulations remain in circulation.
If you are considering Ozempic—whether as a pill, injection, or a compounded version—talk with your healthcare provider and review your health history, genetic background, and lifestyle goals. Widespread interest has led to changing availability, promising new forms, and more transparent labeling, especially after recent updates about kidney and pancreatic risks.
To sum up, Ozempic continues to make waves as both a treatment for diabetes and a potent tool for weight loss. With fresh news about new pill forms, higher effective doses, genetic influences, and ongoing legal cases, it’s important to stay informed and make choices based on both science and your personal health needs.
Thanks for tuning in to Ozempic Weightloss Unlocked. Don’t forget to subscribe to stay up to date on the latest developments. This has been a Quiet Please production, for more check out quiet please dot ai.
Some great Deals https://amzn.to/49SJ3Qs
For more check out http://www.quietplease.ai
This content was created in partnership and with the help of Artificial Intelligence AI
Mark as Played
Transcript
Episode Transcript
Available transcripts are automatically generated. Complete accuracy is not guaranteed.
Speaker 1 (00:00):
Welcome to Ozempic Weight Loss Unlocked, where we dive into
the latest breakthroughs and controversies surrounding ozempic, its medical use,
and its impact on everyday wellness. The big headline this
month is the arrival of a new pill form of
semaglue tide, the main ingredient in ozempic. According to the
New England Journal of Medicine, people who took this daily
pill lost almost fourteen percent of their body weight over
(00:22):
sixty four weeks, compared to just two percent for those
on a picebo. Fifty percent of the patients shared at
least fifteen percent of their weight, with nearly a third
losing twenty percent or more. Novo Nordisk, the company that
makes ozempic, announced even stronger results for those who stuck
to their treatment plan, with close to seventeen percent average
(00:42):
weight loss. This pill, pending approval, could be a game
changer for people who prefer not to take injections on
the injectable front. Clinical trials featured in the Lancet indicate
that a higher seven point two milligram weekly dose of
semaglue tide in adults without diabetes led to almost nineteen
percent average weight loss higher than what seen with lower doses.
(01:05):
These numbers highlight ongoing efforts to increase the effectiveness of
ozempic for those struggling with obesity. Yet it's crucial to
balance these promising results with real world insights. The Mayo
Clinic and NYU langone Health recently compared ozeenpic's results to
traditional weight loss surgery like gastric bypass and sleeve gastrectomy.
Their research revealed that surgery is five times more effective
(01:28):
than GLP one drugs such as ozepic, with surgical patients
losing an average of fifty eight pounds after two years
versus just twelve pounds for those on the drug for
six months. Experts also noted that only thirty percent of
patients stick with GLP one drugs for longer than a year,
and real world weight loss may be lower than trial
results suggest. Surgery, however, isn't without its risks, including potential infections,
(01:54):
blood clots, and harnias, and requires strict diet and lifestyle
changes afterward. Turning to genetics, Cleveland Clinic research shows that
the effectiveness of ozepic may depend on your DNA, a
specific variant in the neurobeachin gene seems to make some
people much more responsive to these medications, leading to eighty
two percent higher odds of substantial weight loss. This new
(02:17):
insight could help doctor's tailor treatments so patients get therapies
most suited to their genetic profile. Lifestyle stakes are high,
and so are concerns about side effects and safety. Recent
studies report that ozempic may cause severe conditions such as gastroparesis,
bowel blockages, pancreatic and kidney injuries, and vision problems. Even
(02:37):
hair loss is emerging as a potentially significant side effect,
especially for women. According to recent findings, female users experienced
about twice the rate of hair loss compared to those
not using ozempic. Because of these risks, there are currently
over two thousand active lawsuits against Novo Nordisk and other
GLP one manufacturers, with ongoing multidistrict litigation. These lawsuits alleged
(03:01):
that the companies did not give enough warning about the dangers,
and some patients claim life changing or life threatening complications.
Compounded GLP one drugs made in pharmacies rather than by
pharmaceutical companies, became popular when a zeenpic was in short supply. However,
the FDA warns that compounded drugs can be risky because
they're not evaluated for safety or effectiveness. While the shortage
(03:25):
has officially ended, compounded formulations remain in circulation. If you
are considering ozepic, whether as a pill, injection or a
compounded version, talk with your health care provider and review
your health history, genetic background, and lifestyle goals. Widespread interest
has led to changing availability, promising new forms, and more
transparent labeling, especially after recent updates about kidney and pancreatic risks.
(03:50):
To sum up, ozepic continues to make waves as both
a treatment for diabetes and a potent tool for weight loss.
With fresh news about new pill forms, high effective doses,
genetic influences, and ongoing legal cases, it's important to stay
informed and make choices based on both science and your
personal health needs. Thanks for tuning in to a zenpic
(04:12):
Weight Loss Unlocked. Don't forget to subscribe to stay up
to date on the latest developments. This has been a
quiet please production. For more check out Quiet Please dot
ai
Welcome to Ozempic Weight Loss Unlocked, where we dive into
the latest breakthroughs and controversies surrounding ozempic, its medical use,
and its impact on everyday wellness. The big headline this
month is the arrival of a new pill form of
semaglue tide, the main ingredient in ozempic. According to the
New England Journal of Medicine, people who took this daily
pill lost almost fourteen percent of their body weight over
(00:22):
sixty four weeks, compared to just two percent for those
on a picebo. Fifty percent of the patients shared at
least fifteen percent of their weight, with nearly a third
losing twenty percent or more. Novo Nordisk, the company that
makes ozempic, announced even stronger results for those who stuck
to their treatment plan, with close to seventeen percent average
(00:42):
weight loss. This pill, pending approval, could be a game
changer for people who prefer not to take injections on
the injectable front. Clinical trials featured in the Lancet indicate
that a higher seven point two milligram weekly dose of
semaglue tide in adults without diabetes led to almost nineteen
percent average weight loss higher than what seen with lower doses.
(01:05):
These numbers highlight ongoing efforts to increase the effectiveness of
ozempic for those struggling with obesity. Yet it's crucial to
balance these promising results with real world insights. The Mayo
Clinic and NYU langone Health recently compared ozeenpic's results to
traditional weight loss surgery like gastric bypass and sleeve gastrectomy.
Their research revealed that surgery is five times more effective
(01:28):
than GLP one drugs such as ozepic, with surgical patients
losing an average of fifty eight pounds after two years
versus just twelve pounds for those on the drug for
six months. Experts also noted that only thirty percent of
patients stick with GLP one drugs for longer than a year,
and real world weight loss may be lower than trial
results suggest. Surgery, however, isn't without its risks, including potential infections,
(01:54):
blood clots, and harnias, and requires strict diet and lifestyle
changes afterward. Turning to genetics, Cleveland Clinic research shows that
the effectiveness of ozepic may depend on your DNA, a
specific variant in the neurobeachin gene seems to make some
people much more responsive to these medications, leading to eighty
two percent higher odds of substantial weight loss. This new
(02:17):
insight could help doctor's tailor treatments so patients get therapies
most suited to their genetic profile. Lifestyle stakes are high,
and so are concerns about side effects and safety. Recent
studies report that ozempic may cause severe conditions such as gastroparesis,
bowel blockages, pancreatic and kidney injuries, and vision problems. Even
(02:37):
hair loss is emerging as a potentially significant side effect,
especially for women. According to recent findings, female users experienced
about twice the rate of hair loss compared to those
not using ozempic. Because of these risks, there are currently
over two thousand active lawsuits against Novo Nordisk and other
GLP one manufacturers, with ongoing multidistrict litigation. These lawsuits alleged
(03:01):
that the companies did not give enough warning about the dangers,
and some patients claim life changing or life threatening complications.
Compounded GLP one drugs made in pharmacies rather than by
pharmaceutical companies, became popular when a zeenpic was in short supply. However,
the FDA warns that compounded drugs can be risky because
they're not evaluated for safety or effectiveness. While the shortage
(03:25):
has officially ended, compounded formulations remain in circulation. If you
are considering ozepic, whether as a pill, injection or a
compounded version, talk with your health care provider and review
your health history, genetic background, and lifestyle goals. Widespread interest
has led to changing availability, promising new forms, and more
transparent labeling, especially after recent updates about kidney and pancreatic risks.
(03:50):
To sum up, ozepic continues to make waves as both
a treatment for diabetes and a potent tool for weight loss.
With fresh news about new pill forms, high effective doses,
genetic influences, and ongoing legal cases, it's important to stay
informed and make choices based on both science and your
personal health needs. Thanks for tuning in to a zenpic
(04:12):
Weight Loss Unlocked. Don't forget to subscribe to stay up
to date on the latest developments. This has been a
quiet please production. For more check out Quiet Please dot
ai
Popular Podcasts
Stuff You Should Know
If you've ever wanted to know about champagne, satanism, the Stonewall Uprising, chaos theory, LSD, El Nino, true crime and Rosa Parks, then look no further. Josh and Chuck have you covered.
Cardiac Cowboys
The heart was always off-limits to surgeons. Cutting into it spelled instant death for the patient. That is, until a ragtag group of doctors scattered across the Midwest and Texas decided to throw out the rule book. Working in makeshift laboratories and home garages, using medical devices made from scavenged machine parts and beer tubes, these men and women invented the field of open heart surgery. Odds are, someone you know is alive because of them. So why has history left them behind? Presented by Chris Pine, CARDIAC COWBOYS tells the gripping true story behind the birth of heart surgery, and the young, Greatest Generation doctors who made it happen. For years, they competed and feuded, racing to be the first, the best, and the most prolific. Some appeared on the cover of Time Magazine, operated on kings and advised presidents. Others ended up disgraced, penniless, and convicted of felonies. Together, they ignited a revolution in medicine, and changed the world.
The Joe Rogan Experience
The official podcast of comedian Joe Rogan.